US Patent Issued to CYTOLYNX THERAPEUTICS HONG KONG on Nov. 25 for "Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,922, issued on Nov. 25, was assigned to CYTOLYNX THERAPEUTICS HONG KONG Ltd. (Hong Kong).

"Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity" was invented by Ning Li (Jiangsu, China), Guoqing Cao (Jiangsu, China), Guojun Lang (Shanghai), Chanjuan Liu (Shanghai) and Yuhao Hu (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is an isolated monoclonal antibody targeting B-cell maturation antigen (BCMA), the antibody can bind to both human BCMA and monkey BCMA. Also provided are a nucleic acid encoding the antibody, a method for producing the antibody, and a pharmaceutical composition comprising the an...